Browse drugs

…elial growth factor (anti-VEGF) agents, such as aflibercept and ranibizumab, are widely used. Although generally safe, they carry a risk of…

…tients (10 injections); faricimab 94 patients (321 injections); ranibizumab 37 patients (127 injections).Classified by most frequent diagno…

…bercept in eyes with treatment-naïve nAMD following an on-label aflibercept treatment protocol; however, real-world extended durability rem…

…tion was 87.3±106.1 µm with aflibercept and 113.1±136.7 µm with faricimab. Adjusted mean reductions were 95.4 µm and 99.8 µm, respectivel…

…ticipants (1026 biosimilar, 1018 reference) were included. Five aflibercept biosimilars were evaluated, representing more than 50% of the e…

…ti-angiogenic therapy, mainly aflibercept and bevacizumab, with faricimab as a second-line option. Personalised treatments and optimised …

…naïve patients experienced modest improvement in visual acuity. Aflibercept enabled extended injection intervals in both groups, particular…

…: 1.42; 95% CI: 1.24 to 1.63), compared with those treated with ranibizumab, and specifically also a higher risk of acute kidney injury (HR…

…subfield thickness (CST) (390.13 µm vs 334.20 µm, p=0.033) than aflibercept patients. Baseline HbA1c (p=0.012) and number of bevacizumab in…

…ain—ranibizumab, aflibercept (2 mg and 8 mg), brolucizumab, and faricimab—each differing in dosing interval, mechanism, and cost. Compara…

…and DME are leading causes of vision loss, with ranibizumab and aflibercept as key treatments. However, frequent monthly injections create …

…III randomised controlled trials (RCTs) evaluating ranibizumab, brolucizumab, aflibercept, and faricimab in nAMD. Baseline characteristics i…